If you blinked, you might have missed it. Cellectar Biosciences (CLRB) shares rallied almost 12% on Tuesday after the company dropped some impressive clinical data. But Wednesday's premarket tells a different story — shares are slipping, down about 4% as of early trading. So what's going on?

The short answer: a classic biotech tug-of-war between promising science and a stock that's been beaten down for a year. Let's unpack it.

The CLOVER WaM Data That Got Everyone Excited

Cellectar's Phase 2b CLOVER WaM trial is targeting Waldenström macroglobulinemia, a rare type of blood cancer. The headline number: an overall response rate of 83.6% in patients with relapsed or refractory disease. That's not just a blip — it's the kind of data that makes oncologists sit up and take notice.

Even more telling is the median duration of response: 17.8 months. That suggests the treatment isn't just working initially; it's keeping the cancer at bay for a meaningful stretch. The drug in question, Iopofosine I 131, is the centerpiece of Cellectar's pipeline, and the company is now gearing up for a confirmatory randomized study. They've also locked in financing of up to $140 million to push toward potential regulatory submissions in both the U.S. and Europe.

That's a lot of positive noise. So why isn't the stock holding its gains?

The Technical Picture: Healing, But Not Healed

Cellectar's stock has had a rough 12 months — down nearly 56%. That kind of drawdown leaves scars. Even after Tuesday's rally, the stock is trading at $3.05 in premarket, which is only 5.6% above its 20-day simple moving average of $2.81. That's a short-term win, but zoom out: it's still 21.2% below its 200-day SMA of $3.77. In other words, the stock is bouncing, but it hasn't escaped the long-term downtrend.

The MACD indicator, which measures momentum, is above its signal line — a positive sign that selling pressure is easing. But the overall trend remains bearish until proven otherwise. Traders are watching two key levels: resistance at $3.50, where previous rebounds have stalled, and support at $3.00, where buyers have stepped in before. With the stock hovering near $3.05, it's dangerously close to that support level.

Momentum vs. The Market: A Mixed Signal

On the bright side, Cellectar scores an 8.17 on momentum relative to the broader market, according to market data. That's a strong reading, suggesting the stock is outperforming the overall market in terms of price momentum — at least for now. But momentum can be fickle, especially for a stock that's near its 52-week low of $2.43.

The verdict? Cellectar is a momentum-driven story right now, powered by clinical data and financing news. But the technicals are still healing, and the stock needs to hold above $3.00 and eventually break through $3.50 to convince the skeptics. Investors should keep an eye on upcoming earnings and regulatory milestones — those will be the real catalysts.

For now, Wednesday's premarket dip looks like profit-taking after Tuesday's pop, not a fundamental reversal. The CLOVER WaM data is real, the financing is in place, and the science is compelling. But in biotech, the stock doesn't always move in a straight line — especially when it's trying to climb out of a 55% hole.